Alli is now out. The news we have been looking at for months is here. Alli, which is the over the counter version of Xenical for loss is now on the market so that people can use this as a aid to their loss program. I have said for years that you can not trust any pills to have you lose and I am still a little apprehensive to recommend that people use Alli to try to lose as the most important things in your control program are proper eating and exercise. Here is the press release for the product
Before you go out and buy Alli I just wanted to let you know that in researching this product I looked for a natural alternative. I have found one product that does what Alli does but is natural, cheaper and best of all has no side effects. That product is called Avatrim. Check out Avatrim before you go out to purchase Alli.
GlaxoSmithKline Consumer Healthcare announces today that the U.S. Food and Drug Administration (FDA) approved the -loss product orlistat 60 mg capsules for over-the-counter (OTC) use in the United States. GSK Consumer Healthcare will market OTC orlistat under the brand name alli(TM) (pronounced AL-eye). Approved for use by over adults in conjunction with a reduced-calorie, low-fat diet, alli helps people lose 50 percent more than with diet alone. alli is the only FDA-approved -loss product available to consumers without a prescription, and it is the first clinically-proven over- the-counter product to be combined with a comprehensive support program. alli is expected to be available in stores nationwide by summer 2007. This approval marks the start of an educational program that includes a series of resources online at myalli.com.
GSK Consumer Healthcare selected alli as the brand name because it conveys the concept of partnership with consumers in their -loss efforts. Consumers spend billions of dollars each year on fad diets, unproven miracle pills, and potentially unsafe -loss supplements that may not work. alli is the clinically proven option to these hyped, quick-fix products that mislead over adults away from -loss strategies that are backed by medical science. With alli, consumers have access to an individually tailored online action plan that provides support and the necessary tools to help them lose 50 percent more than with diet alone.
Caroline Apovian, M.D., Director of the Center for Nutrition and Weight Management at Boston Medical Center welcomed the FDA decision. “I applaud the alli program for stressing the importance of a reduced-calorie, low-fat diet in conjunction with a -loss medicine proven to be safe and effective. This lines up with research that shows even modest, gradual loss provides significant health benefits.” Apovian adds, “More and more people each year — now two-thirds of all American adults — are over or obese and still gaining weight.
Desperate to lose this excess , people resort to all types of extreme methods that promise everything and deliver no real results. Extremely restrictive diets are unrealistic to maintain, even for a couple of weeks. Dieters end up gaining more than they initially lost. It’s time consumers readjust their thinking to realize positive results.”
Why Alli is Different
Unlike other products on store shelves, alli is a proven medicine with a comprehensive support program. To help consumers get off to a successful start, the alli package will include Welcome and Companion Guides, a Guide to Healthy Eating, a Daily Journal, a Calorie and Fat Counter, Quick Fact Cards, and free access to an individualized online action plan at myalli.com.
“With Alli, we’re excited to offer a revolutionary approach to loss,” says Steven L. Burton, Vice President, Weight Control, GlaxoSmithKline Consumer Healthcare. “alli is more than a pill — it’s a comprehensive program that works in conjunction with a sensible diet to increase weight loss. Because loss doesn’t happen overnight, we’re starting to educate consumers now about the importance of realistic expectations, gradual loss and lifestyle changes. That’s the way to see results, and with alli, we know they can do it.”
Starting today, GSK Consumer Healthcare will gear up production to have the product ready for shipment and in stores by the summer. The company is using this period to build awareness and understanding about the product and its intended user — with the message — alli is not for everyone. It’s for the committed consumer who can follow a reduced-calorie, low-fat diet. For this consumer, alli will provide a unique, proven approach to loss, offering straight talk, educational tools and an online support program — myalli.com.
How to Use alli
alli, the only FDA-approved -loss product soon to be available without a prescription, is indicated for loss in over adults 18 years and older when used along with a reduced-calorie, low-fat diet. The recommended dose of alli is one 60 mg capsule three times a day with meals containing fat.
Taken at meal-time, alli works by blocking about 25 percent of the fat in the food a person eats. Because of the way it works, alli must be used in conjunction with a reduced-calorie, low-fat diet containing about 15 grams of fat per meal. The guides and information supplied in the alli package help the consumer to control the amount of fat in their meals, and to follow an appealing, reduced-calorie, low-fat diet. Consuming a meal with too much fat, while taking alli, can result in bowel changes such as having an urgent need to use the bathroom. These changes, called treatment effects, generally occur in the first weeks of treatment, are not harmful, and can be managed by following the recommended diet with about 15 grams of fat per meal. Users should take a multivitamin once a day, at bedtime, because alli can reduce the absorption of some vitamins.
Safety and Efficacy
alli (60 mg orlistat capsules) is safe and effective when used as directed. As the most extensively studied -loss medication on the market, the safety and efficacy of orlistat is very well established. A higher dose of orlistat has been marketed as the prescription drug Xenical(R) (orlistat 120 mg capsules) in the U.S. since 1999 and is supported by nine years of worldwide use in 145 other countries. Orlistat experience in more than 25 million patient treatments and more than 100 clinical studies with more than 30,000 patients is unprecedented. One of these studies with Xenical is the four-year landmark XENDOS trial conducted by Roche, its inventor and manufacturer. This study is the longest study ever conducted for a -loss medicine.
Xenical (orlistat 120 mg capsules) will remain available by prescription for those who should be treated under the care of a physician. Xenical will continue to be manufactured and sold by Roche.
For more information on alli, go to myalli.com.
About Over and Obesity
Currently, approximately 65 percent of U.S. adults are over or obese, according to the National Institutes of Health. Research suggests that over individuals appear to be on the pathway to obesity.(i, ii) Over and obesity are associated with an increased risk of developing health problems such as hypertension, type 2 diabetes and heart disease.(iii) Factors that can contribute to over include an abundance of high-calorie foods, low levels of physical activity, behavior, environment, and genetics.(iv) Multiple studies have shown that a modest reduction in improves health outcomes significantly in over or obese patients